Hikma Pharmaceuticals (Hikma Pharmaceuticals) Inventories, Finished Goods : $375 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Hikma Pharmaceuticals Inventories, Finished Goods?

Hikma Pharmaceuticals's quarterly finished goods increased from Dec. 2022 ($309 Mil) to Jun. 2023 ($312 Mil) and increased from Jun. 2023 ($312 Mil) to Dec. 2023 ($375 Mil).

Hikma Pharmaceuticals's annual finished goods increased from Dec. 2021 ($269 Mil) to Dec. 2022 ($309 Mil) and increased from Dec. 2022 ($309 Mil) to Dec. 2023 ($375 Mil).

Hikma Pharmaceuticals Inventories, Finished Goods Historical Data

The historical data trend for Hikma Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Inventories, Finished Goods Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

251.00

327.00

269.00

309.00

375.00

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Inventories, Finished Goods	Get a 7-Day Free Trial															269.00	-	309.00	312.00	375.00

Hikma Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Hikma Pharmaceuticals (Hikma Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (OTCPK:HKMPF) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HIKl:UK HIK:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.